Key facts
- Dewpoint Therapeutics’s last known valuation is $500.0M (Feb 2022).
- It has raised $345.3M across 3 recorded rounds; the latest was Later Stage VC ($59.1M) in Sep 2025.
- Notable investors include General Catalyst, SoftBank Investment Advisers, Alexandria Venture Investments, Mirae Asset Capital, ARCH Venture Partners — 18 tracked in total.
- Dewpoint Therapeutics has filed 3 Form Ds with the SEC since 2020, most recently Sep 2025 ($59.1M sold to 21 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 18 names
- ·Watchlist + deal alerts for Dewpoint Therapeutics
Funding rounds
3 roundsAbout Dewpoint Therapeutics
Developer of an AI-powered healthcare technology platform designed to identify novel drugs across a wide spectrum of diseases. The company's platform facilitates a proprietary end-to-end experimental platform and uses machine-learning-based image analysis tools for visualizing condensates to prevent harmful protein sequestration, enabling healthcare providers to have access to new therapies to address unmet needs.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2018
- Employees
- 97
- Website
- dewpointx.com/
- Ownership
- Privately Held (backing)
Dewpoint Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Dewpoint Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Dewpoint Therapeutics in its N-PORT filings yet. We sweep new filings monthly.